NewsRoom Articles - Page 150 of 154 - PsychedelicNewsWire (PNW)

ThursdayJan 25, 2018 3:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids Uplisted to OTCQX® Best Market Licensing model generates profit margins in excess of 90 percent A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://cnw.fm/Eay21). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly…

TuesdayJan 23, 2018 3:47 pm

Grey Cloak Tech’s (GRCK) Recent Eqova Acquisition Positions the Company for Growth on Booming CBD Market

Hemp-derived cannabidiol (CBD) sales projected to surpass $1 billion in five years Grey Cloak Tech has acquired Eqova Life Sciences, an established producer of a range of clinical-grade CBD products This acquisition strengthens Grey Cloak’s position in this market sector and is likely to accelerate its growth On the back of several forecasts of explosive growth in the cannabidiol (CBD) market, Grey Cloak Tech, Inc. (OTCQB: GRCK) has made a strategic decision to focus its efforts in this sector. The Hemp Business Journal reports projected growth of 700 percent by 2020, to reach annual sales of $2.1 billion, according to…

TuesdayJan 23, 2018 1:07 pm

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs Active pharmaceutical ingredient market expected to exceed $239 billion by 2025 19 patent applications filed in U.S. and internationally encompassing 44 countries Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million…

TuesdayJan 16, 2018 2:03 pm

Earth Science Tech, Inc. (ETST) is “One to Watch”

Biotech company focused on production of cutting-edge industrial hemp, cannabis/cannabidiol (CBD) products R&D efforts include nutraceuticals, pharmaceuticals, bioceuticals, phytoceuticals and cosmeceuticals catering to health, wellness and alternative medicine markets International provisional patent application targets CBD’s powerful medicinal benefits Integration of CBD molecule with generic drug molecules opens new medical frontier U.S. consumer market for cannabinoid-based pharmaceuticals estimated at $50 billion by 2029 Medical diagnostic device MSN-2 slated for clinical tests to validate detection of various STDs Global market for diagnostic testing of STDs expected to reach $108.5 billion by 2019 Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology…

WednesdayDec 27, 2017 3:49 pm

World Health Organization Officially Rules CBD Should Not be a Scheduled Drug

The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int) WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile” MCOA is committed to the development of high quality CBD-based products The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report…

TuesdayDec 26, 2017 1:08 pm

India Globalization Capital, Inc. (NYSE: IGC) Targets February 2018 International Patent Filing for Eating Disorder Drug

Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s IGC-506 is a combination therapy developed from cannabis extracts and other compounds that’s designed to treat multiple types of eating disorders in humans and animals India Globalization Capital, Inc. (NYSE American: IGC) (FRA: IGS1) anticipates a Patent Cooperation Treaty (“PCT”) filing application by February 28, 2018, for IGC-506, which is designed…

FridayDec 08, 2017 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

MondayDec 04, 2017 9:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

WednesdayNov 29, 2017 9:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive Company generates revenue from out-licensing its technology The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit. Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids.…

TuesdayNov 07, 2017 11:05 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Supplements Popular Beverage with Legal CBD

Unique patented drug delivery platform Active in world’s largest beverage market Technology that compliments rather than competes with CBD companies An old and popular beverage is being supplemented in a healthy, flavorful way now that Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is on the scene. Having increased its ownership stake in PoViva Tea, LLC from 51% to 100%, the innovative drug delivery biotech plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. After water, tea is the most widely consumed beverage in the world and is an ideal adjuvant…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000